Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferatory cytotoxic and apoptotic properties
- 113 Downloads
Temozolomide is an alkylating agent which is used in glioblastoma treatment. We aimed to investigate the effects of different concentrations of temozolomide and exposure time on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9 and VEGF. U87MG cells were cultured in different temozolomide concentrations and incubation time and the effects of temozolomide on inducing apoptosis was investigated. The levels of VEGF and CXCR4 expression were measured by RT-PCR and flowcytometry. Moreover, MMP2 and MMP9 activity and expression were assessed by ELISA and zymography. CXCR4 and VEGF expression levels decreased upon applying higher concentration of temozolomide. MMP2 and MMP-9 had lower activity in cells with longer exposure time or higher doses of temozolomide. Temozolomide induces the apoptosis in U87MG glioblastoma cells at therapeutic or higher dose. It is capable of decreasing their expression levels of VEGF and CXCR4.
KeywordsCXCR4 MMP2 MMP9 Temozolomide U87MG VEGF
Primary brain tumor
Central nervous system
Blood brain barrier
This work was performed in partial fulfillment of the requirements for, Pharm. Dr. of Seyedsaber Mirabdaly in the faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran. The authors gratefully acknowledge the Research Council of Kermanshah University of Medical Sciences (Grant Number: 90076) for the financial support.
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Seyedsaber Mirabdaly, Daniel Elieh Ali Komi and Amir Kiani. The first draft of the manuscript was written by Amir Kiani and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
This work was supported by Research Council of Kermanshah University of Medical Sciences.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Berger G, Grauwet K, Zhang H, Hussey AM, Nowicki MO, Wang DI, Chiocca EA, Lawler SE, Lippard SJ (2018) Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models. Cancer Lett 416:138–148. https://doi.org/10.1016/j.canlet.2017.11.041 CrossRefPubMedGoogle Scholar
- 12.Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR (2016) CXCR4 increases in vivo glioma perivascular invasion, and reduces radiation induced apoptosis: a genetic knockdown study. Oncotarget 7(50):83701–83719. https://doi.org/10.18632/oncotarget.13295 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Gagner JP, Sarfraz Y, Ortenzi V, Alotaibi FM, Chiriboga LA, Tayyib AT, Douglas GJ, Chevalier E, Romagnoli B, Tuffin G, Schmitt M, Lemercier G, Dembowsky K, Zagzag D (2017) Multifaceted C-X-C chemokine receptor 4 (CXCR4) inhibition interferes with anti-vascular endothelial growth factor therapy-induced glioma dissemination. Am J Pathol 187(9):2080–2094. https://doi.org/10.1016/j.ajpath.2017.04.020 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Liu H, Zeng Z, Wang S, Li T, Mastriani E, Li QH, Bao HX, Zhou YJ, Wang X, Liu Y, Liu W, Hu S, Gao S, Yu M, Qi Y, Shen Z, Wang H, Gao T, Dong L, Johnston RN, Liu SL (2017) Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther 18(12):990–999. https://doi.org/10.1080/15384047.2017.1394542 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Khadijeh N, Daniel Elieh Ali K, Habibolah K, Ali M, Asad V-R, Hamid Reza A, Mohammad Rasoul G, Amir K (2018) Investigation of serum levels and activity of matrix metalloproteinases 2 and 9 (MMP2, 9) in opioid and methamphetamine-dependent patients. Acta Med Iran 56:559–562Google Scholar
- 19.Farina P, Tabouret E, Lehmann P, Barrie M, Petrirena G, Campello C, Boucard C, Graillon T, Girard N, Chinot O (2017) Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. J Neurooncol 132(3):433–437. https://doi.org/10.1007/s11060-017-2385-0 CrossRefPubMedGoogle Scholar
- 20.Kim SY, Lee EJ, Woo MS, Jung JS, Hyun JW, Min SW, Kim DH, Kim HS (2008) Inhibition of matrix metalloproteinase-9 gene expression by an isoflavone metabolite, irisolidone in U87MG human astroglioma cells. Biochem Biophys Res Commun 366(2):493–499. https://doi.org/10.1016/j.bbrc.2007.11.178 CrossRefPubMedGoogle Scholar
- 23.Buijs N, Oosterink JE, Jessup M, Schierbeek H, Stolz DB, Houdijk AP, Geller DA, van Leeuwen PA (2017) A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. Angiogenesis 20(4):557–565. https://doi.org/10.1007/s10456-017-9567-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Azambuja JH, da Silveira EF, de Carvalho TR, Oliveira PS, Pacheco S, do Couto CT, Beira FT, Stefanello FM, Spanevello RM, Braganhol E (2017) Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. Biochim Biophys Acta 1861:2652–2662. https://doi.org/10.1016/j.bbagen.2017.07.007 CrossRefGoogle Scholar
- 26.Hassler MR, Sax C, Flechl B, Ackerl M, Preusser M, Hainfellner JA, Woehrer A, Dieckmann KU, Rossler K, Prayer D, Marosi C (2015) Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. Oncology 88(3):173–179. https://doi.org/10.1159/000368903 CrossRefPubMedGoogle Scholar
- 35.Haghnavaz N, Asghari F, Elieh Ali Komi D, Shanehbandi D, Baradaran B, Kazemi T (2018) HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines. Artif Cells Nanomed Biotechnol 46(3):518–523. https://doi.org/10.1080/21691401.2017.1326927 CrossRefPubMedGoogle Scholar
- 37.Huang H, Liu T, Guo J, Yu L, Wu X, He Y, Li D, Liu J, Zhang K, Zheng X, Goodin S (2017) Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures. Bioorg Med Chem Lett 27(11):2286–2291. https://doi.org/10.1016/j.bmcl.2017.04.047 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Hsu EL, Chen N, Westbrook A, Wang F, Zhang R, Taylor RT, Hankinson O (2008) CXCR4 and CXCL12 down-regulation: a novel mechanism for the chemoprotection of 3,3’-diindolylmethane for breast and ovarian cancers. Cancer Lett 265(1):113–123. https://doi.org/10.1016/j.canlet.2008.02.033 CrossRefPubMedGoogle Scholar
- 40.Gabelloni P, Da Pozzo E, Bendinelli S, Costa B, Nuti E, Casalini F, Orlandini E, Da Settimo F, Rossello A, Martini C (2010) Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience 168(2):514–522. https://doi.org/10.1016/j.neuroscience.2010.03.064 CrossRefPubMedGoogle Scholar